Frontiers in Nephrology (Apr 2024)

Chemotherapy-induced tubulopathy: a case report series

  • Mario Alamilla-Sanchez,
  • Juan Daniel Diaz Garcia,
  • Valeria Yanez Salguero,
  • Fleuvier Morales Lopez,
  • Victor Ulloa Galvan,
  • Francisco Velasco Garcia-Lascurain,
  • Benjamin Yama Estrella

DOI
https://doi.org/10.3389/fneph.2024.1384208
Journal volume & issue
Vol. 4

Abstract

Read online

Acquired tubulopathies are frequently underdiagnosed. They can be characterized by the renal loss of specific electrolytes or organic solutes, suggesting the location of dysfunction. These tubulopathies phenotypically can resemble Bartter or Gitelman syndrome). These syndromes are infrequent, they may present salt loss resembling the effect of thiazides (Gitelman) or loop diuretics (Bartter). They are characterized by potentially severe hypokalemia, associated with metabolic alkalosis, secondary hyperaldosteronism, and often hypomagnesemia. Tubular dysfunction has been described as nephrotoxic effects of platinum-based chemotherapy. We present 4 cases with biochemical signs of tubular dysfunction (Bartter-like/Gitelman-like phenotype) related to chemotherapy.

Keywords